Clinical Trial Update: Duration of Protection: GSK DTaP Vaccines

View source ↗

Summary

A completed clinical trial from GlaxoSmithKline evaluated the duration of protection provided by GSK's DTaP vaccine against diphtheria, tetanus, and pertussis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Infanrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphtheria, Acellular Pertussis | Status: COMPLETED